Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2020-09-23
- Employees
- -
- Market Cap
- -
- Website
- https://www.wp-hz.com/
Clinical Trials
3
Active:0
Completed:3
Trial Phases
3 Phases
Phase 1:1
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (33.3%)Phase 2
1 (33.3%)Phase 3
1 (33.3%)Study of WPV01 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: WPV01 Dose 1-4Drug: WPV01 Dose 5-8 and RitonavirDrug: WPV01 Dose 9-12Drug: WPV01 Dose 13-15 and RitonavirDrug: WPV01 Dose 16
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT06205329
- Locations
- 🇨🇳
Shulan(Hangzhou) Hospital, Hangzhou, China
Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
- Target Recruit Count
- 1350
- Registration Number
- NCT06197217
- Locations
- 🇨🇳
China Japan Friendship Hospital, Beijing, Beijing, China
Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05752175
- Locations
- 🇨🇳
Shulan(Hangzhou) Hospital, Hangzhou, China
News
No news found